The ambivalent role of apoptosis in experimental autoimmune encephalomyelitis and multiple sclerosis

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4453-4464

  Reichardt, Holger M ^a   Lühder, Fred ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Apoptosis; Bcl 2; Caspase; EAE; Fas; Glucocorticoid; Leukocyte; MS; Oligodendrocyte

Indexed keywords

CASPASE; FAS ANTIGEN; FAS LIGAND; GLUCOCORTICOID; PROTEIN BCL 2;

ALLERGIC ENCEPHALOMYELITIS; APOPTOSIS; ARTICLE; AXONAL INJURY; DISEASE COURSE; HUMAN; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TISSUE INJURY;

ADOLESCENT; ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; LYMPHOCYTES; MULTIPLE SCLEROSIS;

EID: 84866371505     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502224     Document Type: Article

References (162)

1. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407: 796-801.
2. Pender MP, Rist MJ. Apoptosis of inflammatory cells in immune control of the nervous system: Role of glia. Glia 2001; 36: 137-144.
3. Dittel BN, Merchant RM, Janeway CA. Evidence for Fasdependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 1999; 162: 6392-400.
4. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129: 1953-1971.
5. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-354.
6. Bouillet P, O'Reilly LA. CD95, BIM and T cell homeostasis. Nat Rev Immunol 2009; 9: 514-519.
7. Wang XD. The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922-2933.
8. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
9. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005; 5: 189-200.
10. Strasser A, Jost PJ, Nagata S. The Many Roles of FAS Receptor Signaling in the Immune System. Immunity 2009; 30: 180-192.
11. Luo X, Budihardjo I, Zou H, Slaughter C, Wang XD. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
12. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005; 11: 725-730.
13. Penninger JM, Kroemer G. Mitochondria, AIF and caspases - rivaling for cell death execution. Nat Cell Biol 2003; 5: 97-99.
14. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid- induced apoptosis of lymphoid cells in vivo. Blood 2005; 106: 4131-4138.
15. Rathmell JC, Lindsten T, Zong WX, Cinalli RM, Thompson CB. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol 2002; 3: 932-939.
16. Bouillet P, Metcalf D, Huang DCS, et al. Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738.
17. Ranger AM, Zha JP, Harada H, et al. Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9324-9329.
18. Han JW, Flemington C, Houghton AB, et al. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc Natl Acad Sci USA 2001; 98: 11318-11323.
19. Erlacher M, Labi V, Manzl C, et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006; 203: 2939-2951.
20. Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: Lessons from knockout mice. Immunity 1999; 10: 629-639.
21. Yi CH, Yuan JY. The Jekyll and Hyde Functions of Caspases. Developmental Cell 2009; 16: 21-34.
22. Salmena L, Lemmers B, Hakem A, et al. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 2003; 17: 883-895.
23. Salmena L, Hakem R. Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. J Exp Med 2005; 202: 727-732.
24. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking Caspase 9. Cell 1998; 94: 325-337.
25. Kuida K, Zheng TS, Na SQ, et al. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. Nature 1996; 384: 368-372.
26. Holcik M, Korneluk RG. XIAP, the guardian angel. Nature Reviews Molecular Cell Biology 2001; 2: 550-556.
27. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opn Cell Biol 1999; 11: 255-260.
28. Suda T, Takahashi T, Golstein P, Nagata S. Molecular-Cloning and Expression of the Fas Ligand, A Novel Member of the Tumor-Necrosis-Factor Family. Cell 1993; 75: 1169-1178.
29. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas Ligand in Cells of T-Cell Lineage. J Immunol 1995; 154: 3806-3813.
30. Watanabefukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen That Mediates Apoptosis. Nature 1992; 356: 314-317.
31. Takahashi T, Tanaka M, Brannan CI, et al. Generalized Lymphoproliferative Disease in Mice, Caused by A Point Mutation in the Fas Ligand. Cell 1994; 76: 969-976.
32. Zhang JK, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392: 296-300.
33. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. Embo J 1998; 17: 706-718.
34. Zornig M, Hueber AO, Evan G. P53-dependent impairment of Tcell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998; 8: 467-470.
35. Tourneur L, Chiocchia G. FADD: a regulator of life and death. Trends Immunol 2010; 31: 260-269.
36. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63: 60-72.
37. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-541.
38. Memon SA, Moreno MB, Petrak D, Zacharchuk CM. Bcl-2 Blocks Glucocorticoid-Induced But Not Fas-Induced Or Activation-Induced Apoptosis in A T-Cell Hybridoma. J Immunol 1995; 155: 4644-4652.
39. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-Deficient Mice Demonstrate Fulminant Lymphoid Apoptosis, Polycystic Kidneys, and Hypopigmented Hair. Cell 1993; 75: 229-240.
40. Yin XM, Wang K, Gross A, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 1999; 400: 886-891.
41. Wang DP, Müller N, McPherson KG, Reichardt HM. Glucocorticoids engage different signal transduction pathways to induce apoptosis in thymocytes and mature T cells. J Immunol 2006; 176: 1695-1702.
42. Marsden VS, O'Connor L, O'Reilly LA, et al. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419: 634-637.
43. O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL et al. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 2002; 9: 832-841.
44. Yang Y, Fang SY, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000; 288: 874-877.
45. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
46. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204: 208-231.
47. Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23: 683-747.
48. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Ann Rev Neurosci 2008; 31: 247-269.
49. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Current Opinion in Neurology 2009; 22: 219-225.
50. Sadovnick AD, Ebers GC, Dyment DA, et al. Evidence for genetic basis of multiple sclerosis. Lancet 1996; 347: 1728-30.
51. Holmoy T, Harbo H, Vartdal F, Spurkland A. Genetic and Molecular Approaches to the Immunopathogenesis of Multiple Sclerosis: An Update. Curr Mol Med 2009; 9: 591-611.
52. Lauer K. Environmental risk factors in multiple sclerosis. Exp Rev Neurother 2010; 10: 421-440.
53. Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56: 308.
54. Stadelmann C, Albert M, Wegner C, Bruck W. Cortical pathology in multiple sclerosis. Curr Opn Neurol 2008; 21: 229-234.
55. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206: 165-171.
56. Van der Walt A, Butzkueven H, Kolbe S, et al. Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade. Pharmacology & Therapeutics 2010; 126: 82-93.
57. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprote in-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006; 116: 2393-2402.
58. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell B cell cooperation. J Clin Invest 2006; 116: 2385-2392.
59. Na SY, Cao Y, Toben C, Nitschke L, Stadelmann C, Gold R et al. Nave CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain 2008; 131: 2353-2365.
60. Flügel A, Berkowicz T, Ritter T, et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001; 14: 547-560.
61. Bartholomäus I, Kawakami N, Odoardi F, Schlager C, Miljkovic D, Ellwart JW et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94-U104.
62. Tuohy VK, Yu M, Yin L, et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1998; 164: 93-100.
63. Sriram S, Steiner I. Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann Neurol 2005; 58: 939-945.
64. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006; 60: 12-21.
65. Becher B, Durell BG, Noelle RJ. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest 2002; 110: 493-497.
66. Ferber IA, Brocke S, TaylorEdwards C, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalolmyelitis (EAE). J Immunol 1996; 156: 5-7.
67. Willenborg DO, Fordham S, Bernard CCA, Cowden WB, Ramshaw IA. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 1996; 157: 3223-3227.
68. Haak S, Gyulveszi G, Becher B. Th17 cells in autoimmune disease: changing the verdict. Immunotherapy 2009; 1: 199-203.
69. Segal B. Th17 cells in autoimmune demyelinating disease. Sem Immunopathol 2010; 32: 71-77.
70. van den Brandt J, Fischer HJ, Walter L, Hünig T, Klöting I, Reichardt HM. Type 1 Diabetes in BioBreeding Rats Is Critically Linked to an Imbalance between Th17 and Regulatory T Cells and an Altered TCR Repertoire. J Immunol 2010; 185: 2285-2294.
71. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin- 12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
72. Hofstetter HH, Ibrahim SM, Koczan D, et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005; 237: 123-130.
73. Haak S, Croxford AL, Kreymborg K, et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J Clin Invest 2009; 119: 61-69.
74. Kreymborg K, Etzensperger R, Dumoutier L, et al. IL-22 is expressed by TH17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007; 179: 8098-8104.
75. McQualter JL, Darwiche R, Ewing C, et al. Granulocyte macrophage colony-stimulating factor: A new putative therapeutic target in multiple sclerosis. J Exp Med 2001; 194: 873-881.
76. Nowak EC, Weaver CT, Turner H, et al. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009; 206: 1653-1660.
77. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes. J Immunol 2009; 183: 7169-7177.
78. Zhou L, Chong MMW, Littman DR. Plasticity of CD4(+) T Cell Lineage Differentiation. Immunity 2009; 30: 646-655.
79. Friese MA, Fugger L. Autoreactive CD8(+) T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128: 1747-1763.
80. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis le sions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192: 393-404.
81. Sobottka B, Harrer MD, Ziegler U, et al. Collateral Bystander Damage by Myelin-Directed CD8(+) T Cells Causes Axonal Loss. Am J Pathol 2009; 175: 1160-1166.
82. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212.
83. Jiang H, Curran S, Ruiz-Vazquez E, Liang B, Winchester R, Chess L. Regulatory CD8(+) T cells fine-tune the myelin basic proteinreactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2003; 100: 8378-8383.
84. Montero E, Nussbaum G, Kaye JF, et al. Regulation of Experimental Autoimmune Encephalomyelitis by CD4(+), CD25(+) and CD8(+) T cells: analysis using depleting antibodies. J Autoimmun 2004; 23: 1-7.
85. Cabarrocas J, Bauer J, Piaggio E, Liblau R, Lassmann H. Effective and selective immune surveillance of the brain by MHC class Irestricted cytotoxic T lymphocytes. Eur J Immunol 2003; 33: 1174-1182.
86. Pender MP, Nguyen KB, McCombe PA, Kerr JFR. Apoptosis in the Nervous-System in Experimental Allergic Encephalomyelitis. J Neurol Sci 1991; 104: 81-87.
87. Pender MP, McCombe PA, Yoong G, Nguyen KB. Apoptosis of Alpha-Beta Lymphocytes-T in the Nervous-System in Experimental Autoimmune Encephalomyelitis - Its Possible Implications for Recovery and Acquired Tolerance. J Autoimmun 1992; 5: 401-410.
88. Schmied M, Breitschopf H, Gold R, et al. Apoptosis of TLymphocytes in Experimental Autoimmune Encephalomyelitis - Evidence for Programmed Cell-Death As A Mechanism to Control Inflammation in the Brain. Am J Pathol 1993; 143: 446-452.
89. Kohji T, Matsumoto Y. Coexpression of Fas/FasL and Bax on brain and infiltrating T cells in the central nervous system is closely associated with apoptotic cell death during autoimmune encephalomyelitis. J Neuroimmunol 2000; 106: 165-171.
90. Moon C, Kim S, Wie M, et al. Increased expression of p53 and Bax in the spinal cords of rats with experimental autoimmune encephalomyelitis. Neurosci Lett 2000; 289: 41-44.
91. Tabi Z, McCombe PA, Pender MP. Apoptotic Elimination of VBeta- 8.2(+) Cells from the Central-Nervous-System During Recovery from Experimental Autoimmune Encephalomyelitis Induced by the Passive Transfer of V-Beta-8.2(+) Encephalitogenic T-Cells. Eur J Immunol 1994; 24: 2609-2617.
92. Bauer J, Bradl M, Hickey WF, et al. T-cell apoptosis in inflammatory brain lesions - Destruction of T cells does not depend on antigen recognition. Am J Pathol 1998; 153: 715-724.
93. Zettl UK, Gold R, Toyka KV, Hartung HP. Intravenous Glucocorticosteroid Treatment Augments Apoptosis of Inflammatory TCells in Experimental Autoimmune Neuritis (Ean) of the Lewis Rat. J Neuropathol Exp Neurol 1995; 54: 540-547.
94. Issazadeh S, Abdallah K, Chitnis T, et al. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest 2000; 105: 1109-16.
95. Okuda Y, Okuda M, Bernard CCA. The suppression of T cell apoptosis influences the severity of disease during the chronic phase but not the recovery from the acute phase of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol 2002; 131: 115-125.
96. Podojil JR, Kohm AP, Miller SD. CD4(+) T cell expressed CD80 regulates central nervous system effector function and survival during experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 2948-2958.
97. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immunol 2003; 4: 410-415.
98. Lev N, Barhum Y, Melamed E, Offen D. Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice. Neurosci Lett 2004; 359: 139-142.
99. Ludwinski MW, Sun J, Hilliard B, Gong SY, Xue F, Carmody RJ et al. Critical roles of Bim in T cell activation and T cell-mediated autoimmune inflammation in mice. J Clin Invest 2009; 119: 1706-1713.
100. Okuda Y, Bernard CCA, Fujimura H, Yanagihara T, Sakoda S. Fas has a crucial role in the progression of experimental autoimmune encephalomyelitis. Mol Immunol 1998; 35: 317-326.
101. Sabelko KA, Kelly KA, Nahm MH, Cross AH, Russell JH. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J Immunol 1997; 159: 3096-3099.
102. Waldner H, Sobel RA, Howard E, Kuchroo VK. Fas- and FasLdeficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 1997; 159: 3100-3103.
103. Suvannavejh GC, Dal Canto MC, Matis LA, Miller SD. Fasmediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2000; 105: 223-231.
104. Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 1999; 189: 1195-1205.
105. Ciusani E, Gelati M, Frigerio S, et al. Modulation of experimental allergic encephalomyelitis in Lewis rats by administration of a peptide of Fas ligand. J Autoimmun 2001; 17: 273-280.
106. Zhu B, Luo LQ, Chen YL, Paty DW, Cynader MS. Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 1561-1569.
107. Dsouza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184: 2361-2370.
108. Sun J, Hilliard B, Xu LY, Chen YHH. Essential roles of the Fasassociated death domain in autoimmune encephalomyelitis. J Immunol 2005; 175: 4783-4788.
109. Tseveleki V, Bauer J, Taoufik E, et al. Cellular FLIP (long isoform) overexpression in T cells drives Th2 effector responses and promotes immunoregulation in experimental autoimmune encephalomyelitis. J Immunol 2004; 173: 6619-626.
110. Semra YK, Seidi OA, Sharief MK. Overexpression of the apoptosis inhibitor FLIP in T cells correlates with disease activity in multiple sclerosis. J Neuroimmunol 2001; 113: 268-274.
111. Screpanti I, Morrone S, Meco D, et al. Steroid Sensitivity of Thymocyte Subpopulations During Intrathymic Differentiation - Effects of 17-Beta-Estradiol and Dexamethasone on Subsets Expressing T-Cell Antigen Receptor Or Il-2 Receptor. J Immunol 1989; 142: 3378-3383.
112. Wüst S, van den Brandt J, Tischner D, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008; 180: 8434-8443.
113. Macphee IAM, Antoni FA, Mason DW. Spontaneous-Recovery of Rats from Experimental Allergic Encephalomyelitis Is Dependent on Regulation of the Immune-System by Endogenous Adrenal Corticosteroids. J Exp Med 1989; 169: 431-445.
114. Smith T, Schmied M, Hewson AK, Lassmann H, Cuzner ML. Apoptosis of T cells and macrophages in the central nervous system of intact and adrenalectomized Lewis rats during experimental allergic encephalomyelitis. J Autoimmun 1996; 9: 167-174.
115. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58: 91-7.
116. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000; 123: 1431-1441.
117. Schmidt J, Metselaar JM, Wauben MHM, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 2003; 126: 1895-1904.
118. Linker RA, Weller C, Lühder F, et al. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: Long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp Neurol 2008; 211: 397-406.
119. White CA, McCombe PA, Pender MP. The roles of Fas, Fas ligand and Bcl-2 in T cell apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. J Neuroimmunol 1998; 82: 47-55.
120. Tischner D, van den Brandt J, Weishaupt A, Lühder F, Herold MJ, Reichardt HM. Stable silencing of the glucocorticoid receptor in myelin-specific T effector cells by retroviral delivery of shRNA: Insight into neuroinflammatory disease. Eur J Immunol 2009; 39: 2361-2370.
121. Nguyen KB, McCombe PA, Pender MP. Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. J Neuropathol Exp Neurol 1997; 56: 58-69.
122. Wüst S, Tischner D, John M, et al. Therapeutic and Adverse Effects of a Non-Steroidal Glucocorticoid Receptor Ligand in a Mouse Model of Multiple Sclerosis. Plos One 2009; 4.
123. van Loo G, Sze M, Bougarne N, et al. Antiinflammatory Properties of a Plant-Derived Nonsteroidal, Dissociated Glucocorticoid Receptor Modulator in Experimental Autoimmune Encephalomyelitis. Mol Endocrinol 2010; 24: 310-322.
124. De Bosscher K, Van den Berghe W, Beck IME, et al. A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci USA 2005; 102: 15827-15832.
125. Markus MA, Morris BJ. Resveratrol in prevention and treatment of common clinical conditions of aging. Clin Interv Aging 2008; 3: 331-339.
126. Kwon HS, Oft M. The ups and downs of SIRT1. Trends Biochem Sci 2008; 33: 517-525.
127. Zhang JN, Lee SM, Shannon S, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009; 119: 3048-3058.
128. Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P. Resveratrol (trans-3,5,4 '-trihydroxystilbene) ameliorates experimentalallergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 2007; 72: 1508-1521.
129. Sharief MK, Semra YK. Upregulation of the inhibitor of apoptosis proteins in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol 2001; 119: 350-357.
130. Moore CS, Hebb ALO, Blanchard MM, et al. Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE). J Neuroimmunol 2008; 203: 79-93.
131. Zehntner SP, Bourbonniere L, Moore CS, et al. X-linked inhibitor of apoptosis regulates T cell effector function. J Immunol 2007; 179: 7553-7560.
132. LaCasse EC, Kandimalla ER, Winocour P, et al. Application of XIAP antisense to cancer and other proliferative disorders - Development of AEG35156/GEM (R) 640. Therapeutic Oligonucleotides: Transcriptional and Translational Strategies for Silencing Gene Expression 2005; 1058: 215-234.
133. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of Oligodendroglia Pathology in Multiple-Sclerosis. Brain 1994; 117: 1311-1322.
134. Dowling P, Husar W, Menonna J, Donnenfeld H, Cook S, Sidhu M. Cell death and birth in multiple sclerosis brain. J Neurol Sci 1997; 149: 1-11.
135. Cudrici C, Niculescu T, Niculescu F, Shin ML, Rus H. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement. J Rehab Res Dev 2006; 43: 123-131.
136. Bonetti B, Pohl J, Gao YL, Raine CS. Cell death during autoimmune demyelination: Effector but not target cells are eliminated by apoptosis. J Immunol 1997; 159: 5733-5741.
137. Dsouza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184: 2361-2370.
138. Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356: 827-828.
139. Matysiak M, Jurewicz A, Jaskolski D, Selmaj K. TRAIL induces death of human oligodendrocytes isolated from adult brain. Brain 2002; 125: 2469-2480.
140. Song KM, Chen YG, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 2000; 191: 1095-1103.
141. Lünemann JD, Waiczies S, Ehrlich S, et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002; 168: 4881-4888.
142. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005; 46: 421-432.
143. Chung IY, Benveniste EN. Tumor Necrosis Factor-Alpha Production by Astrocytes - Induction by Lipopolysaccharide, Ifn-Gamma, and Il-1-Beta. J Immunol 1990; 144: 2999-3007.
144. Hisahara S, Shoji S, Okano H, Miura M. ICE/CED-3 family executes oligodendrocyte apoptosis by tumor necrosis factor. J Neurochem 1997; 69: 10-20.
145. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial Cell Cytotoxicity of Oligodendrocytes Is Mediated Through Nitric-Oxide. J Immunol 1993; 151: 2132-2141.
146. Hisahara S, Araki T, Sugiyama F, et al. Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. Embo J 2000; 19: 341-348.
147. Hisahara S, Yuan JY, Momoi T, Okano H, Miura M. Caspase-11 mediates oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination. J Exp Med 2001; 193: 111-22.
148. Furlan R, Martino G, Galbiati F, et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999; 163: 2403-2409.
149. Weerth SH, Rus H, Shin ML, Raine CS. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am J Pathol 2003; 163: 1069-1680.
150. Niculescu T, Weerth S, Niculescu F, et al. Effect of complement C5 on Fas system in experimental autoimmune encephalomyelitis. Mol Immunol 2004; 41: 285.
151. Soane L, Rus H, Niculescu F, Shin ML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of Bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol 1999; 163: 6132-6138.
152. Deshpande RV, Goust JM, Hogan EL, Banik NL. Calpain Secreted by Activated Human Lymphoid-Cells Degrades Myelin. J Neurosci Res 1995; 42: 259-265.
153. Das A, Guyton MK, Butler JT, Ray SK, Banik NL. Activation of Calpain and Caspase Pathways in Demyelination and Neurodegeneration in Animal Model of Multiple Sclerosis. Cns & Neurological Disorders-Drug Targets 2008; 7: 313-320.
154. Shields DC, Tyor WR, Deibler GE, Hogan EL, Banik NL. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci USA 1998; 95: 5768-5772.
155. Shields DC, Schaecher KE, Saido TC, Banik NL. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 1999; 96: 11486-11491.
156. Guyton MK, Wingrave JM, Yallapragada AV, et al. Upregulation of calpain correlates with increased neuro degeneration in acute experimental auto-immune encephalomyelitis. J Neurosci Res 2005; 81: 53-61.
157. Cerghet M, Skoff RP, Bessert D, Zhang Z, Mullins C, Ghandour MS. Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci 2006; 26: 1439-1447.
158. Guyton MK, Brahmachari S, Das A, et al. Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem 2009; 110: 1895-1907.
159. Guyton MK, Das A, Samantaray S, et al. Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 2010; 88: 2398-2408.
160. Huang EJ, Reichardt LF. Neurotrophins: Roles in neuronal development and function. Annual Review of Neuroscience 2001; 24: 677-736.
161. Linker RA, Maurer M, Gaupp S, et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620-624.
162. Linker R, Gold R, Lühder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol 2009; 29: 43-68.